-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on AbbVie, Maintains $214 Price Target

Benzinga·04/17/2025 15:33:19
Listen to the news
Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $214 price target.